Diabetes drug fights memory loss in mice with Alzheimer’s
Originally developed to treat type 2 diabetes, the triple GLP-1/GIP/glucagon receptor agonist was found to 'significantly reverse memory loss'.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.